Hims & Hers: The Rebirth of a Growth Story?
Through the official partnership with Novo Nordisk, Hims & Hers eliminates the existential threat of protracted patent lawsuits and transforms its image from an opportunistic imitator to a legitimized market leader.
Reading Time: 2 minutes
The partnership between Hims & Hers and Novo Nordisk marks a turning point in the still young history of the digital health platform. For months, uncertainty about the legal viability of the business model weighed heavily on the stock price. Hims & Hers had greatly benefited from the boom in GLP-1 drugs by relying on so-called "compounding," creating its own mixtures during shortages of the original products. This put them on a direct collision course with pharmaceutical giants, which had repeatedly caused problems, particularly with Novo...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
